China imposes $ 60 experimental vaccine against coronavirus
BEIJING – A $ 60 double-dose experimental coronavirus vaccine is being made available to some residents in the eastern Chinese city, health officials have said, the first detail of a large-scale rollout for an asymmetrical vaccine.
Officials in the city of Jiaxing said that people aged between 18 and 59 with “urgent needs” can consult clinics for the Synovac Biotech vaccine on Thursday to groups such as officer medical personnel.
The statement by Jiaxing’s Center for Disease Control and Prevention did not specify what constituted “immediate needs”.
Officials did not reveal how many people were given the vaccine in the city, which comes in two doses, is administered 28 days apart, and costs a total of 400 yuan ($ 59).
According to officials, China has already provided an experimental vaccine to thousands of essential workers in ports, hospitals and other high-risk areas across the country.
But even as 11 Chinese vaccines have entered clinical trials – four in advanced phase three trials – none have been approved for mass market delivery.
China is desperate to win a global race for the vaccine against a virus in the central city of Wuhan, as it seeks to complete its narrative of recovering from public health and economic disaster.
China has approved some candidates for emergency use, with officials saying they have not seen serious adverse reactions.
Beijing has also made bold predictions on a wider rollout before the end of the year as it fights a storm of international criticism over its initial settlement of the outbreak.
Health officials told a press conference last month that the country expected to be able to produce 610 million vaccine doses annually by the end of the year would be stressful.
Chinese President Xi Jinping has also previously announced that Chinese vaccines will be made a “global public good”.
China has signed a bid led by the World Health Organization to ensure that Kovid-19 vaccines are distributed to developing countries, the largest economy involved in an effort to control the epidemic.
Beijing has not provided details of how much it will pay for the deal, which has a $ 2 billion fundraising goal and aims to provide vaccines to 92 low- and middle-income countries in the future.